跳至主要内容
临床试验/NCT03648814
NCT03648814招募中不适用

Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial

Prince of Songkla University2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
2
主要终点
regression of nevolascularization

研究概览

简要总结

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

详细描述

The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of neovascular glaucoma
  • The patients having IOP > 21 mmHg, having the indication for trabeculectomy
  • The patients' age of at least 18-year-old
  • The patients having visual potential at least hand motion.
  • Present of NVI or NVA.
  • Willing and able to provide informed consent to participate in the study
  • Able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits

排除标准

  • One eye patient
  • Patients having severe corneal edema or total hyphema obscure NVI or NVA view.
  • Cannot obtain endothelial cell count.
  • History of bevacizumab or fluorescence dye allergy.
  • Active infectious ocular disease including endophthalmitis and corneal ulcer
  • History of systemic disease including ischemic heart disease, cerebrovascular disease, end-stage renal disease, liver failure, uncontrolled hypertension
  • Has or planning to be pregnant or breastfeeding

结局指标

主要结局

regression of nevolascularization

时间窗: 2 months

Amount of nevolascular of iris and angle regression

次要结局

  • Injection complication(2 days)
  • IOP reduction(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Weerawat Kiddee

Assoc. Prof.

Prince of Songkla University

研究点 (2)

Loading locations...

相似试验